CLOV logo

Clover Health Investments, Corp. Stock Price

NasdaqGS:CLOV Community·US$2.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 98 Fair Values set on narratives written by author

CLOV Share Price Performance

US$3.98
0.81 (25.55%)
US$2.82
Fair Value
US$3.98
0.81 (25.55%)
41.3% overvalued intrinsic discount
US$2.82
Fair Value
Price US$3.98
AnalystConsensusTarget US$2.82
AnalystHighTarget US$3.20
AnalystLowTarget US$3.00

CLOV Community Narratives

·
Fair Value US$2.82 41.3% overvalued intrinsic discount

Margin Pressures and Healthcare Reforms Will Influence Future Medicare Advantage Dynamics

1users have liked this narrative
0users have commented on this narrative
43users have followed this narrative
·
Fair Value US$3.2 24.4% overvalued intrinsic discount

Digital Healthcare And Medicare Advantage Will Unlock Long-term Opportunities

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value US$3 32.7% overvalued intrinsic discount

Rising Costs And Regulation Will Erode Medicare Advantage Profitability

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
US$3
32.7% overvalued intrinsic discount
Profit Margin
0.97%
Future PE
60.62x
Price in 2029
US$3.67

Trending Discussion

Updated Narratives

CLOV logo

CLOV: Interoperability Progress And Execution Efforts Will Shape Balanced Future Outlook

Fair Value: US$2.82 41.3% overvalued intrinsic discount
43 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CLOV logo

CLOV: Interoperability Progress And 2026 Guidance Will Support Earnings Breakthrough Potential

Fair Value: US$3.2 24.4% overvalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CLOV logo

CLOV: Medicare Advantage Expansion And Buybacks Will Support Long-Term Upside

Fair Value: US$3 32.7% overvalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

1 Risk
3 Rewards

Clover Health Investments, Corp. Key Details

US$2.2b

Revenue

US$1.8b

Cost of Revenue

US$405.8m

Gross Profit

US$462.7m

Other Expenses

-US$56.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.11
18.36%
-2.58%
0%
View Full Analysis

About CLOV

Founded
2014
Employees
724
CEO
Andrew Toy
WebsiteView website
www.cloverhealth.com

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.

Recent CLOV News & Updates

Seeking Alpha May 20

Clover Health's Bullish Setup Still Looks Compelling

Summary Clover Health Investments, Corp. (CLOV) is executing a credible turnaround, reporting its first-ever positive GAAP net income and strong Q1 2026 results. CLOV’s Medicare Advantage membership surged 51% YoY with over 95% retention, driving improving cohort profitability and robust gross margins. Disciplined SG&A management and a quality edge, evidenced by a top HEDIS score, support margin expansion and Star rating sustainability. I maintain a Strong Buy rating; risk/reward remains compelling as profitability, cost control, and SaaS upside could drive further multiple expansion. Read the full article on Seeking Alpha

Recent updates

No updates